C=x Bonded Directly Or Indirectly By An Acyclic Carbon Or Carbon Chain To Ring Carbon Of The Five-membered Hetero Ring (e.g., Tryptophan, Etc.) (x Is Chalcogen) Patents (Class 514/419)
-
Publication number: 20100204295Abstract: A method of treatment for treating, preventing, inhibiting or reducing allergic disease or its effects in a subject, comprises administering to the subject an effective amount of an immunomodulator compound, which composes an aromatic or heterocyclic amino acid residue or a derivative thereof. Preferably, the immunomodulatory compound is a dipeptide which comprises a D- or L-tryptophan residue.Type: ApplicationFiled: May 13, 2008Publication date: August 12, 2010Applicant: SCICLONE PHARMACEUTICALS, INC.Inventors: Alexandr A. Kolobov, Andrey S. Simbirtsev
-
Publication number: 20100204254Abstract: The present invention discloses statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) consistently and significantly increased endothelial cell thrombomodulin protein and functional activity. Statins also abrogated the downregulation of thrombomodulin that occurs in response to radiation injury. These results indicate that preserving or restoring endothelial thrombomodulin expression and function by statins may be useful in a variety of disorders associated with widespread endothelial dysfunction such as sepsis, adult respiratory distress syndrome, and normal tissue radiation injury.Type: ApplicationFiled: January 29, 2010Publication date: August 12, 2010Applicant: The University of Arkansas for Medical SciencesInventors: Martin K. Hauer-Jensen, Louis M. Fink, Jawahar Lal Mehta, Junru Wang, Jacob Joseph
-
Publication number: 20100204195Abstract: Amorphous HMG CoA reductase inhibitors, especially amorphous atorvastatin, are described. Also described are pharmaceutical combinations comprising amorphous HMG CoA reductase inhibitors in combination with cholesterol absorption inhibitors or fibrates. A method of manufacturing the compositions using a hot melt extrusion process are also described.Type: ApplicationFiled: July 28, 2008Publication date: August 12, 2010Applicant: CIPLA LIMITEDInventors: Amar Lulla, Geena Malhotra
-
Patent number: 7772284Abstract: An inexpensive, easily available, and convenient method of treating or preventing a virus infection is provided. The present invention relates to a method for the treatment or prevention of virus infections using polybiguanide-based compounds administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof. The invention relies on the unique biochemical reaction in which polybiguanide-based compounds interfere with the spread of virus within or between organisms. The compositions and formulations described in the present invention are effective means to reduce the infectivity of the human immunodeficiency virus type 1 (HIV-1), and human herpes simplex viruses, and also to kill the causative organisms of many other sexually transmitted diseases (STDs).Type: GrantFiled: August 27, 2003Date of Patent: August 10, 2010Inventors: Mohamed E. Labib, Richard F. Stockel
-
Patent number: 7772216Abstract: The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, immune system activity, Type II diabetes, and obesity.Type: GrantFiled: August 16, 2005Date of Patent: August 10, 2010Assignee: The Research Foundation of State University of New YorkInventors: David G. Hangauer, Jr., Moustafa E. El-Araby, Karen L. Milkiewicz
-
Publication number: 20100197687Abstract: There is provided compounds of formula I, wherein T, Y, X1, R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.Type: ApplicationFiled: December 22, 2005Publication date: August 5, 2010Inventors: Benjamin Pelcman, Kristofer Olofsson, Martins Katkevics, Vita Ozola, Edgars Suna, Ivars Kalvins, Peteris Trapencieris, Dace Katkevica, Wesley Schaal
-
Publication number: 20100196469Abstract: The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Atorvastatin or Fluvastatin or salts thereof, in combination with colloidal clay such as Attapulgite, and a process for the preparation thereof by direct compression.Type: ApplicationFiled: June 25, 2007Publication date: August 5, 2010Applicant: PHARMATHEN S.A.Inventors: Evangelos Karavas, Efthimios Koutris, Elli Ioannidou, Vicky Samara, Dimitrios Bikiaris
-
Publication number: 20100197734Abstract: A compound of formula (I) or of formula (II) wherein X is oxygen or sulfur, and Y is a residue of pipecolic acid or a residue of an amino acid, preferably a naturally occurring amino acid.Type: ApplicationFiled: July 11, 2008Publication date: August 5, 2010Applicant: NABRIVA THERAPEUTICS AGInventors: Klaus Thirring, Werner Heilmayer
-
Publication number: 20100196286Abstract: Methods, devices and kits for treating sleep disorders, anxiety disorders, and developmental disorders, and/or for inducing an arousable state of sedation in a subject, are described. For example, inhalation methods, devices and kits for treating insomnia, anxiety and/or ADHD using one or more ?2-adrenergic agonists such as dexmedetomidine or clonidine are described.Type: ApplicationFiled: December 1, 2009Publication date: August 5, 2010Inventors: Thomas A. ARMER, Robert O. Cook, Terry Alfredson, Anthony Sun
-
Publication number: 20100197758Abstract: The invention provides for ischemia/reperfusion protection compositions having one or more ketone bodies and melatonin. The invention also provides for methods of using such compositions to reduce or prevent ischemia/reperfusion injury due to blood loss, stroke or cardiopulmonary arrest or surgery.Type: ApplicationFiled: April 11, 2008Publication date: August 5, 2010Inventors: Matthew T. Andrews, Lester R. Drewes, Greg Beilman
-
Publication number: 20100197626Abstract: The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression.Type: ApplicationFiled: May 8, 2007Publication date: August 5, 2010Inventors: Lisa A. Paige, Matthew W. Mitchell, Anne Evans, Don Harvan
-
Publication number: 20100197708Abstract: Indole derivatives that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benzyl derivatives and others are benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.Type: ApplicationFiled: August 7, 2007Publication date: August 5, 2010Inventors: John Jeffrey Talley, Kevin Sprott, James Philip Pearson, G. Todd Milne, Wayne Schairer, Jane Yang, Charles Kim, Timothy Barden, Regina Lundrigan, Ara Mermerian, Mark G. Currie
-
Publication number: 20100189669Abstract: Personal care compositions containing an active selected from the group consisting of phlorogine, phlorgine BG, deoxyArbutin, sucrose dilaurate, bakuchiol, pyrenoine, millet, arlatone dioic acid, cinnamic acid, ferulic acid, achromaxyl, methyl nicotinamide, oil soluble licorice extract, folic acid, undecylenic acid, zinc undecylenate, L-tryptophan, thiamine HCl, hexylresorcinol, lipidami red vine, dragosine, methyl gentisate, inositol, symdiol 68, laminaine, their salts, their derivatives, their precursors, and/or combinations thereof. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.Type: ApplicationFiled: January 25, 2010Publication date: July 29, 2010Inventor: Tomohiro Hakozaki
-
Publication number: 20100189648Abstract: A hydrophobic binding pocket on ubiquitin-protein ligase E3 is described, and used in designing the inhibitors disrupting ubiquitin conjugating enzyme E2 and E3 interaction. Four types of inhibitors designed by using the binding pocket are provided, which can be used for cancer treatment.Type: ApplicationFiled: November 1, 2007Publication date: July 29, 2010Inventors: Lan Huang, Li Xing
-
Publication number: 20100190688Abstract: Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer are provided.Type: ApplicationFiled: July 12, 2005Publication date: July 29, 2010Inventors: Bin Chao, Thomas L. Deckwerth, Paul S. Furth, Steven D. Linton, Alfred P. Spada, Brett R. Ullman, Michael I. Weinhouse
-
Publication number: 20100190768Abstract: The present invention relates to a compound represented by the formula (1) which is useful as a glucocorticoid receptor function regulating agent, an anti-inflammatory agent or an antidiabetic agent, or a pharmaceutically acceptable salt thereof: wherein R1 is aralkyl, etc.; R2 is H, etc.; —W4?W5—W6?W7— is a group of the formula: —CR4?CR5—CR6?CR7— (in which R4, R5, R6 and R7 are independently a group of the formula: -E-A (E is a single bond, etc., A is H or nitro, etc.)), etc.; R8 is a group of the formula: —OR11 (R11 is H, etc.), etc.; R9 is trifluoromethyl, etc.; R10 is a group of the formula: —[C(R13)(R14)]n—R15 (R13 and R14 are independently H, etc., n is an integer of 0 to 10, R15 is a group of the formula: N(R18)R19 (R18 and R19 form a nitrogen-containing heteromonocycle together with a nitrogen atom to which they are bonded), etc.).Type: ApplicationFiled: September 29, 2006Publication date: July 29, 2010Applicant: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshihiko Sone, Rieko Sawaki, Tomoko Nakajima
-
Publication number: 20100184819Abstract: The present invention relates generally to methods for reducing intracranial pressure in a subject. More particularly, the methods of the present invention include administering to the subject an effective amount of a substance P receptor antagonist.Type: ApplicationFiled: July 18, 2008Publication date: July 22, 2010Inventor: Robert Vink
-
Publication number: 20100183658Abstract: The invention provides classes of novel compounds that accelerate peptide loading to DR in the absence of DM and related pharmaceutical compositions. The invention also provides conjugates of these compounds with peptides, antigens or other MHC-based therapeutics, including peptides that self-catalyze their loading onto MHC Class II molecules. Methods are provided for modulating an immune response in a subject. Also disclosed are methods of using the novel compounds, e.g., in combination with MHC-based therapeutics, for the treatment of autoimmune diseases and for the manufacture of medicaments. Methods of improving loading of viral peptides and tumor peptides for enhancing the CD4 T cell response following vaccination against viruses or tumors, and related vaccines, are also provided.Type: ApplicationFiled: March 28, 2008Publication date: July 22, 2010Applicants: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Kai W. Wucherpfennig, Melissa Joy Call, Xuechao Xing, Ross L. Stein, Gregory D. Cuny
-
Patent number: 7758861Abstract: The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates both units in the same molecules. The compounds are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest.Type: GrantFiled: March 21, 2006Date of Patent: July 20, 2010Assignee: Mallinckrodt Inc.Inventors: Raghavan Rajagopalan, Samuel I. Achilefu, Joseph E. Bugaj, Richard D. Dorshow
-
Publication number: 20100178259Abstract: Methods and compositions to prevent scarring of the skin include a matrix metalloproteinase inhibitor and a vehicle suitable for topical application. Scarring and damage to the epidermis and extracellular matrix may be reduced and/or prevented. Following skin damage, application of the matrix metalloproteinase inhibitor reduces expansion of the extracellular matrix portion of the skin compared to untreated skin.Type: ApplicationFiled: January 12, 2010Publication date: July 15, 2010Applicant: The Regents of The University of MichiganInventors: Gary J. Fisher, John J. Voorhees
-
Publication number: 20100178371Abstract: Compositions comprising L-tryptophan and/or 5-hydroxytryptophan are used for preparing a product suitable for sublingual or nasal administration which is helpful in suppressing appetite in such a manner as to promote weight loss in an individual; such compositions furthermore exhibit an antidepressant activity and an antiasthenic effect which makes them helpful in improving tone and mood and the level of attention in an individual. The compositions preferably comprise phenylethylamine in a synergistic combination which substance is contained in an algal plant extract, preferably of Klamath algae.Type: ApplicationFiled: June 3, 2008Publication date: July 15, 2010Inventor: Giulia Federica Merizzi
-
Patent number: 7754896Abstract: The present invention relates to agonists of the S1P4 receptor, which are selective for the S1P4 receptor over one or more of the S1P1, S1P2, S1P3 or S1P5 receptors of at least 10 fold, in particular new indol-alanine derivatives of structure I, process for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them wherein R1 is phenyl or naphthyl, wherein phenyl is substituted by one or two of halogen, C1-6alkyl, C1-6alkoxy or phenylC1-6alkyl; and R2 is hydrogen or C1-6alkyl; in free or salt form.Type: GrantFiled: January 20, 2005Date of Patent: July 13, 2010Assignee: Novartis AGInventors: Kamal Azzaoui, Rochdi Bouhelal, Peter Buehlmayer, Danilo Guerini, Manuel Koller
-
Patent number: 7754679Abstract: Pharmaceutical compositions comprising an aptamer and an amino acid ester or amide or an aptamer; a divalent metal cation; and a carboxylic acid, a phospholipid, a phosphatidyl choline, or a sphingomyelin. Methods of treating or preventing a condition in an animal comprising administering to the animal the pharmaceutical compositions.Type: GrantFiled: April 10, 2006Date of Patent: July 13, 2010Assignee: IDEXX Laboratories, Inc.Inventor: Yerramilli V. S. N. Murthy
-
Patent number: 7754740Abstract: Compounds of the formula (1): in which A, R1, R2 and R3 are as defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.Type: GrantFiled: December 17, 2005Date of Patent: July 13, 2010Assignee: Merck Patent GmbHInventors: Nathalie Adje, Didier Roche, Stéphane Yvon
-
Patent number: 7754736Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4 and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: October 7, 2008Date of Patent: July 13, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Matthias Heinrich Nettekoven, Jean-Marc Plancher, Olivier Roche, Rosa Maria Rodriguez-Sarmiento
-
Publication number: 20100173872Abstract: A composition and method of treating Alzheimer's disease or a dementia of vascular origin are disclosed. The composition and method utilize an endothelin antagonist as the active agent to treat Alzheimer's disease or a dementia of vascular origin in mammals, including humans.Type: ApplicationFiled: January 4, 2010Publication date: July 8, 2010Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventor: Anil Gulati
-
Patent number: 7749530Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.Type: GrantFiled: December 23, 2008Date of Patent: July 6, 2010Assignee: Allergan, Inc.Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Julie A. Wurster, Wendy M. Blanda
-
Patent number: 7750039Abstract: The present invention provides novel compounds of Formula (I) which are CB2 selective ligands useful for the treatment of pain.Type: GrantFiled: February 13, 2009Date of Patent: July 6, 2010Assignee: Abbott LaboratoriesInventors: Jennifer M. Frost, Karin Tietje, Michael J. Dart, Michael D. Meyer
-
Publication number: 20100168092Abstract: The invention relates to medicine, in particular to searching and developing novel medicinal agent for treating pancreatic diabetes. The invention is based on the development of more effective and less toxic medicinal agents based on indole derivatives which exhibit antidiabetic, hypolipidemic, hypoglycemic, hypocholesterolemic activity and insulin resistance-improving actions and the structure of which differs from the structure of traditionally used compounds. The inventive indole derivatives are also low-toxic and easily tolerated.Type: ApplicationFiled: May 22, 2008Publication date: July 1, 2010Inventors: Alexander Victorovich Demin, Vitaly Afanasievich Martianov, Alexander Mihaylovich Shuster
-
Publication number: 20100166889Abstract: The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.Type: ApplicationFiled: December 23, 2009Publication date: July 1, 2010Applicant: LCS GROUP, LLCInventor: Louis Sanfilippo
-
Publication number: 20100167927Abstract: The invention relates to substituted amino-thiourea compounds of formula (I), to the enantiomers, diastereomers and salts thereof and to compositions comprising such compounds. The invention also relates to the use of the substituted amino-thiourea compounds, of their salts or of compositions comprising them for combating animal pests. Furthermore the invention relates also to methods of applying such compounds. The substituted amino-thiourea compounds are defined by the following formula (I): wherein A, B, R1, R2, R3, R4, R5.1, R5.2 and R6 are defined as in the description.Type: ApplicationFiled: May 13, 2008Publication date: July 1, 2010Applicant: BASF SEInventors: Christopher Koradin, Markus Kordes, Ernst Baumann, Ronan Le Vezouet, Deborah L. Culbertson
-
Patent number: 7745479Abstract: The present invention relates to compounds of formula I wherein R1 to R4 and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: November 27, 2006Date of Patent: June 29, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Matthias Nettekoven, Jean-Marc Plancher, Hans Richter, Olivier Roche, Valerie Runtz-Schmitt, Sven Taylor
-
Publication number: 20100160361Abstract: Administration of sPLA2 inhibitors in combination with statins has been found to reduce major adverse cardiac events (MACEs), inflammatory biomarker levels, and LDL-C levels in subjects who have recently experienced an index ACS event to a significantly greater degree than statins alone. These results were unexpected given previous results showing that statins alone are insufficient to satisfactorily reduce MACEs and inflammation in this high-risk population. Therefore, provided herein are methods of treating MACEs, treating ACS, inhibiting inflammation, and lowering cholesterol levels in a subject who has previously experienced an ACS event by administering one or more sPLA2 inhibitors alone or in combination with one or more statins.Type: ApplicationFiled: December 18, 2009Publication date: June 24, 2010Inventors: Colin Hislop, Joaquim Trias, Debra Odink, Paul Truex
-
Publication number: 20100158996Abstract: A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1?) (wherein R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R10)—; R3 and R4 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R9 and R9 are each independently hydrogen atom, C1-C6 alkyl, —CON(R18) (R19) or —COO(R20), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk1 and Alk2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.Type: ApplicationFiled: February 12, 2010Publication date: June 24, 2010Inventors: Atsushi Hagiwara, Yasuhiro Ohe, Naoya Odani, Shizue Watanabe, Taku Ikenogami, Takashi Kawai, Kenya Madono, Toshio Taniguchi
-
Patent number: 7741363Abstract: The invention relates to compounds of formula (I), wherein X, R1, R2, R3, R4 and R5 are as described herein. The invention also includes preparative methods for the preparation of compounds of formula (I). A method for the therapeutic use of the inventive compounds is also disclosed and claimed.Type: GrantFiled: May 14, 2008Date of Patent: June 22, 2010Assignee: Sanofi-AventisInventors: Francis Barth, Claude Vernhet, Murielle Rinaldi-Carmona, CaroleElisabeth Guillaumont-Legeay
-
Patent number: 7741359Abstract: The present invention relates to derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) having improved anti-inflammatory properties useful in the treatment of inflammation, pain and fever. More particularly, NSAIDs are derivatized with a hydrogen sulfide (H2S) releasing moiety to produce novel anti-inflammatory compounds having reduced side effects.Type: GrantFiled: July 18, 2007Date of Patent: June 22, 2010Assignee: Antibe Therapeutics Inc.Inventors: John Wallace, Giuseppe Cirino, Vincenzo Santagada, Giuseppe Caliendo
-
Publication number: 20100151066Abstract: Compositions comprising L-tryptophan, 5-hydroxytryptophan and/or D-Limonene are used for preparing a product suitable for sublingual or nasal administration which is helpful in suppressing appetite in such a manner as to promote weight loss in an individual; such compositions furthermore exhibit an antidepressant activity and an antiasthenic effect which makes them helpful in improving tone and mood and the level of attention in an individual. The compositions preferably comprise phenylethylamine in a synergistic combination which substance is contained in an algal plant extract, preferably of Klamath algae.Type: ApplicationFiled: December 9, 2009Publication date: June 17, 2010Inventor: Giulia Federica MERIZZI
-
Publication number: 20100151058Abstract: Long term weight loss can be achieved and maintained with a formulation of over-the-counter life-enhancing dietary supplements. One or more supplements stimulate the release of serotonin within the brain and one or more supplements stimulate the release of cholecystokinin into the bloodstream. The combined potentiating effect of these two mechanisms on satiety enables greater weight loss than that previously achieved by the individual mechanisms acting alone. A third weight loss mechanism can be achieved with the addition of phenylethylamine. Even more effective weight loss formulations can be achieved with the addition of a blue-green algae, such as aphanizomenon flos aqua, to provide a longer lasting weight loss mechanism.Type: ApplicationFiled: February 22, 2010Publication date: June 17, 2010Inventor: John V. Cappello
-
Patent number: 7737173Abstract: The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: and wherein the variables Y, R4, n, A, X, Z, R1, o, R3, R2 and p are as defined in the specification. These compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, and wound healing.Type: GrantFiled: February 15, 2007Date of Patent: June 15, 2010Assignee: Allergan, Inc.Inventors: Richard L. Beard, John E. Donello, Haiqing Yuan, Diana F. Colon, Tien Duong, Xiaoxia Liu, Yihui Hu
-
Patent number: 7732479Abstract: Indole derivatives, compositions including same, and methods utilizing same for the treatment of amyloid associated diseases, such as type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis, and prion-related encephalopathies are provided.Type: GrantFiled: August 18, 2005Date of Patent: June 8, 2010Assignee: Tel Aviv University Future Technology Development L.P.Inventors: Ehud Gazit, Tomer Cohen
-
Publication number: 20100137363Abstract: The present invention relates generally to substituted indoles and methods of using them.Type: ApplicationFiled: January 29, 2010Publication date: June 3, 2010Applicant: Wyeth LLCInventors: Baihua HU, James W. Jetter
-
Publication number: 20100137284Abstract: The combination of nitric oxide generating compounds which are not dependent upon aldehyde dehydrogenase for bioactivation, or are specifically targeted to nNOS or the sarcoplasmic reticulum of cardiac muscle cells, and xanthine oxidase inhibitors are effective in the treatment of heart disease, specifically congestive heart failure and ischemic coronary disease. This treatment is particularly effective in patients who have particularly heavy oxidative burdens, e.g. diabetics, patients with lung disorders, patients with sickle cell anemia and patients of Asian descent.Type: ApplicationFiled: June 25, 2009Publication date: June 3, 2010Inventors: Jonathan S. Stamler, Gregory T. Went
-
Publication number: 20100137401Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.Type: ApplicationFiled: February 2, 2010Publication date: June 3, 2010Applicant: Incyte CorporationInventors: Wenqing Yao, Colin Zhang, Jincong Zhuo, Meizhong Xu, Konstantinos Agrios, Brian Metcalf
-
Publication number: 20100137400Abstract: The present invention relates to improved pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an HMG-CoA reductase inhibitor, and more particularly Fluvastatin, Atorvastatin or salts thereof in combination with a linear sulphated polysaccharide such as Carrageenan and a method for the preparation thereof.Type: ApplicationFiled: May 12, 2006Publication date: June 3, 2010Applicant: PHARMATHEN S.A.Inventors: Evangelos Karavas, Efthimios Koutris, Elisavet Ioannidou, Eleni Stathaki, Dimitrios Bikiaris
-
Publication number: 20100129311Abstract: The present invention relates to new phenylalanine amide inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 23, 2009Publication date: May 27, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Publication number: 20100130563Abstract: The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.Type: ApplicationFiled: November 20, 2009Publication date: May 27, 2010Applicant: Activesite Pharmaceuticals, Inc.Inventors: Sukanto Sinha, Tamie Jo Chilcote
-
Publication number: 20100119482Abstract: Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and/or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.Type: ApplicationFiled: December 24, 2009Publication date: May 13, 2010Inventors: Anthony Joonkyoo Yun, Partic Yuarn-Bor Lee
-
Publication number: 20100120887Abstract: The present invention relates to low-dose formulations of melatonin, and methods of use thereof, which provide a sustained release of melatonin so as to rapidly increase plasma levels of melatonin, maintain a relatively high level (which mimics the endogenous level of a young subject) for approximately 5-6 hours, and then decrease so as to achieve low levels by early morning (rapid washout), thereby avoiding a “hangover effect”. The sustained release formulations of the invention may be used to treat a variety of sleep-related disorders, including, but not limited to, delayed onset and maintenance forms of insomnia.Type: ApplicationFiled: November 23, 2009Publication date: May 13, 2010Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Michael TERMAN, John Charles HAKALA
-
Publication number: 20100119601Abstract: The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.Type: ApplicationFiled: April 10, 2008Publication date: May 13, 2010Applicant: PHARMACEUTICAL PRODUCTIONS INC.Inventor: John A. McCarty
-
Publication number: 20100119508Abstract: The present invention relates to new phenylacetic acid inhibitors of cyclooxygenase activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 11, 2009Publication date: May 13, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manoucherhr M. Shahbaz